OR WAIT null SECS
© 2023 MJH Life Sciences and BioPharm International. All rights reserved.
© 2023 MJH Life Sciences™ and BioPharm International. All rights reserved.
September 25, 2023
The company is currently developing EVX-101 as an adjunctive treatment for MDD due to patients experiencing an inadequate response to first-line antidepressants such as selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors SNRIs.
August 09, 2023
Stable producer cell lines show real promise despite continued development challenges.
July 06, 2023
Chime Biologics, Leads Biolabs, and BeiGene have formed a three-way collaboration to advance the development and global manufacturing of Leads Biolabs’ lead mAb candidate, LBL-007.
July 02, 2023
Despite many development challenges, stable producer cell lines show real promise.
April 12, 2023
Lives are saved when time from vein to vein decreases.
March 08, 2023
Key challenges posed to autologous and allogeneic treatments could be resolved by in-vivo CAR-T gene therapies.
March 02, 2023
Decreasing vein to vein time saves lives.
February 02, 2023
In vivo CAR-T gene therapies could overcome the challenges faced by autologous and allogeneic treatments.
September 14, 2022
An early drug candidate screening strategy should incorporate clear targets to lessen late-stage failure.
August 10, 2022
Preclinical testing is better able to evaluate complex drug candidates thanks to innovations in animal model approaches.